STAAR Surgical board recommends $28 per share Alcon merger

Go back to STAAR Surgical board recommends $28 per share Alcon merger

STAAR Surgical Board of Directors Unanimously Believes Alcon Merger Maximizes Value for STAAR Stockholders

September 16, 2025 9:10 AM UTC

Provides Greater Value than STAAR Could Achieve on a Standalone Basis in the Foreseeable Future and is the Best Path Forward for STAAR Stockholders

Files Definitive Proxy Materials and Mails Letter to STAAR Stockholders

Encourages Stockholders to Vote FOR the Value Maximizing Alcon Merger Today

LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL) for vision correction, today announced that it... More